The Emmes Corporation today announced that it is the new corporate sponsor of Leadership Montgomery’s Corporate Volunteer Council.
The grant from Emmes will help Leadership Montgomery add new business partners, help existing partners increase the number of employee volunteers, and match volunteer interests with the needs of area non-profit and charitable organizations.
CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases entitled “Preclinical studies of PG70 LEAPS peptide vaccine for rheumatoid arthritis”. The grant in the amount of approximately $1.5 million will provide funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application, by funding GMP manufacturing, IND enabling studies, and additional mechanism of action studies.
Angle plc, a liquid biopsy company, has secured a valuable partnership with molecular testing giant Qiagen and an exclusive option agreement with Queen Mary University of London. Angle is known for Parsortix, its novel system for capturing and harvesting circulating tumor cells (CTCs) from blood.
OVERVIEW: Machfu simplifies the complex landscape of Industrial Internet of Things (IIoT) by easily connecting data at the edge to IoT databases in the cloud for business analytics. Machfu grew out of a simple idea: that developing and maintaining applications in the industrial IoT world should be as easy as it is in the desktop world or the smartphone world.
Startups and entrepreneurs involved with Johns Hopkins Technology Ventures secured hundreds of patents and invention disclosures, and brought in millions of dollars in funding in fiscal year 2017.
WorkSource Montgomery has grown exponentially in its first year, and we are happy to have new staff, a new address to our corporate headquarters and the opportunity to serve our businesses and talent each day. To celebrate a year of accomplishments, let’s take a look back at where we started.
Contrary Capital, a university-focused venture capital fund, officially launched on Monday at 55 colleges across the country, including Hopkins. Contrary works with 100 students to find start-ups and projects within their university communities in which they can invest.
ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s first-in-class dual inhibitor of BET bromodomains and dopamine receptor 2, in ovarian carcinoma. Work will be done under the guidance of Dr. Sherry Wu in the laboratory of Dr. Anil Sood. The program will advance in 2 distinct phases. First the unique mechanism of action of the ConverGene lead compound will be assessed in vitro then clinically relevant activity will be determined utilizing in vivo model systems developed in the Sood lab.
Join BioBuzz along with Double Helix Sponsor CRB and event sponsor ISPE-CBA as we visit 7 Locks Brewing in Rockville for this special networking event. The Science of Beer was created when we learned that many scientists and bbrewers. This is our opportunity to bring our members and brewing professionals together to network and sample some of the tastiest beers. This event has a limit on registration. please don’t sign-up unless you are certain to attend!
TEDCO’s 7th Annual Entrepreneur Expo will bring together all of Maryland’s entrepreneurial resources from across the state into one place, at one time.
You can expect to see 700+ of the region’s top entrepreneurs, small and large business executives, angel and venture capital investors, federal and state economic development officials, university leaders and legislators.
DayZero: Cybersecurity Law and Policy It is no secret that Silicon Valley and Washington have dramatically different workplace cultures and attitudes toward risk and technology. In the valley, savvy entrepreneurs look to disrupt the status quo. Meanwhile in Washington, many of our elected representatives and government personnel are stuck decades in the digital past, forced to use equipment that would be better housed in a museum. This divide inhibits the country’s ability to respond effectively to long-standing problems such as vulnerable critical infrastructure and to adapt in light of new threats such as election interference operations and loss of advanced intelligence capabilities. Washington needs to boost its technical chops and find new ways to recruit private-sector talent.
In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.
Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.
The European Commission approved Tecentriq, also known as atezolizumab, as a monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) after patients have been treated with chemotherapy.
One week until Beta City! Join Betamore + Sagamore Ventures on September 28 for Maryland’s annual celebration of entrepreneurship + technology. Beta City brings together Baltimore’s greatest minds for a day full of pitches, startup demos and a celebration of our growing community.
Brewer’s Alley 124 North Market Street Frederick, MD 21701
Leave the stress of your work day behind and come join friends and colleagues at MTC’s Young Professionals Society networking event. Join us in Frederick for light hors d’oeuvres and a cash bar.
YPS advances young professionals through leadership and professional development, networking opportunities, educational events and community outreach. The society strengthens the life science and technology communities in Maryland by providing an opportunity for collaboration among these two industries.
This group is designed for MTC members 35 years and under. We look forward to seeing you soon!
Institute for Bioscience & Biotechnology Research 9600 Gudelsky Drive Rockville, MD, Maryland 20850
Wednesday, October 4, 2017 from 6:00 PM to 8:00 PM (EDT)
As physicians, scientists and entrepreneurs, sometimes we believe that we can do it all, only to find out that our attempts at practicing law, accounting or financial strategy are many times misguided. Come and learn from experts in the field about the obstacles and opportunities that are ahead of you and how best to navigate these choppy waters!
The market opportunity in health care is huge, and Apple sees health care and wellness as a core part of its app, services, and wearables strategies. Now the company is aiming to become your personal health record, jumping into research, medical devices, and more.
Larger medtech companies have traditionally shied away from investing in the pediatric market, but the landscape is changing. In the last year alone, we witnessed the passage of the 21st Century Cures Act and the signing of the FDA Reauthorization Act (FDARA 2017) into law. The industry is ripe for innovation and these legislative advances present new opportunities to connect innovators with the investment community.
Welcome to ARP Network Quarterly Notes! Our goal is to keep you informed about ARP Network and Agricultural Research Service’s current information. We hope that the notes build networking opportunities for businesses to connect with ARP Network Members. Please help us spread the word by sharing ARP Network Notes statewide with your company contacts, colleagues, other organizations, etc. Thank you!
What is Philips HealthWorks? As a venture capital fund, what qualities do you look for in a partner?
While the Philips HealthWorks team is linked to our Health Technology Venture Fund team at Philips, we see ourselves, first and foremost, as defining a new model for innovation community engagement. Think of Philips HealthWorks as a new front door for early-stage companies to collaborate with our global company.
When a hospital needs to rush a delivery from a lab somewhere else in a densely populated city–for example, when a surgeon needs an urgent biopsy of a tumor in the middle of a surgery to determine how much tissue to remove, or a gunshot victim in the ER needs blood that the hospital doesn’t have in stock–that delivery can sometimes get stuck in traffic. Couriers are also expensive. In Switzerland, hospitals and labs will soon begin using drones to make those deliveries instead.
Top pharma execs at the marquee companies don’t really retire. Some segue quite naturally into venture capital, where their contacts and heavyweight industry reputations can facilitate the growth of little biotech companies at a time the VC crowd is enjoying a prolonged and popular boom.
The 2018 FLC Awards is now open for nominations. One of the most coveted honors in the technology transfer field, the FLC awards have been presented to over 200 federal laboratories since their inception in 1984. Many of our winning technology transfer efforts have gone on to become products and devices that are indispensable in our daily lives.
Margaret Anderson, formerly executive director at Washington-based FasterCures, has joined Deloitte Consulting LLP as a managing director for federal health practice.
Deloitte said Monday Anderson will oversee the firm’s health outcome improvement efforts through the advancement of platforms and collaboration with stakeholders across federal health, life sciences and nonprofit sectors.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
